Prevalence and Burden of Human Immunodeficiency Virus and Hepatitis B Virus Co-infection in Nigeria: A Systematic Review and Meta-Analysis
- *Corresponding Author:
- Lukman Femi Owolabi
Neurology unit, Department of Medicine
Aminu Kano Teaching Hospital
Bayero University, PMB 3452, Kano, Nigeria
E-mail: [email protected]
Received Date: March 09, 2014; Accepted Date: May 02, 2014; Published Date: May 15, 2014
Citation: Owolabi LF, Ibrahim A, Musa BM, Gwaram BA, Dutse AI, et al. (2014) Prevalence and Burden of Human Immunodeficiency Virus and Hepatitis B Virus Co-infection in Nigeria: A Systematic Review and Meta-Analysis. J AIDS Clin Res 5:308. doi:10.4172/2155-6113.1000308
Copyright: © 2014 Owolabi LF, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Background: Studies on HIV/HBV co-infection in Nigeria yielded prevalence ranging between 10% and 70%, giving the widest variation in prevalence of HIV/HBV co-infection from studies emanating from any country all over the world. However, estimation of clinical and public health impacts of HIV/HBV co-infection requires a robust and reliable epidemiological data for an appropriate estimation of the logistical, economic, and humanitarian impact of the two viruses in Nigeria.
Objective: The aim of this review was to estimate the prevalence and burden of HBV infections in HIV-infected patients in Nigeria. Methods: Estimates were derived from a random effects meta-analysis of observational studies reporting the prevalence of HBV/HIV in Nigeria. The derived estimate for the prevalence of HBV/HIV co-infection was applied to the total HIV-infected populations in Nigeria to give an estimated burden of HBV/HIV co-infection in Nigeria.
Result: Thirty three studies with quality data from seventeen states in Nigeria, up to December 16, 2013, were included. I-squared heterogeneity was 98%. Random effect model (REM) estimate of prevalence among HIV-infected patients from the 33 studies was 15% (95% CI 13-17). The prevalence of HIV/HB co-infection among attendees of HIV clinics was 17% [95% CI 13-20], among pregnant HIV-infected patients were 10% [95% CI 6-15], 12% [95% CI 6-17] among HIV-infected children and among newly discovered HIV-infected voluntary blood donor (VBD) patients 10% [95% CI 6-15]. Meta- regression showed no significant associations between the mean age of the patients, the proportion of female patients, year of the study and prevalence of co-infection. The burden of HBV/HIV co-infection in Nigeria, based on the estimate, was 984 000 C.I. [852 800-1115 200].
Conclusion: In Nigeria, the estimated prevalence of HBV/HIV infection is 15% resulting in a substantial burden for the country.